Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers

The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and clinical trials. FDA has recently granted approval to sotora...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Husain Yar, Nagasaka, Misako, Li, Yiwei, Aboukameel, Amro, Uddin, Md. Hafiz, Sexton, Rachel, Bannoura, Sahar, Mzannar, Yousef, Al-Hallak, Mohammed Najeeb, Kim, Steve, Beydoun, Rafic, Landesman, Yosef, Mamdani, Hirva, Uprety, Dipesh, Philip, Philip A., Mohammad, Ramzi M., Shields, Anthony F., Azmi, Asfar S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105196/
https://www.ncbi.nlm.nih.gov/pubmed/35573474
http://dx.doi.org/10.1158/2767-9764.CRC-21-0176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105196/
https://www.ncbi.nlm.nih.gov/pubmed/35573474
http://dx.doi.org/10.1158/2767-9764.CRC-21-0176

Ejemplares similares